Artificial intelligence-based clinical monitoring agents can generate up to $21m in gains per drug development programme, according to a new analysis from Medable and the Tufts Center for the Study of Drug Development (CSDD). The study, based on a benchmarked oncology programme and clinical trial data from Tufts CSDD, found an 82-times return on investment for Phase III trials.
The analysis calculated expected Net Present Value gains of approximately $7.5m for a Phase II trial, $21m for a Phase III trial, and $11.3m for combined Phase II and Phase III development. Direct operating cost reductions in on-site monitoring were estimated at $4.4m per Phase II trial and $5.6m per Phase III study. On-site visits and travel costs are the main drivers of those savings.
Beyond monitoring costs, the study identified administrative off-site task efficiencies worth roughly $600,000 for Phase II and $1.7m for Phase III trials. These reflect clinical research associate time that could be redirected to other studies, though they were excluded from the eNPV calculations.
Eighteen weeks faster to market
Agentic AI can accelerate clinical development by approximately 18 weeks, the study found. Shorter enrolment timelines and earlier database lock bring regulatory submission and commercialisation forward, which increases expected financial value for sponsors.
Ken Getz, Tufts CSDD executive director, said: "The financial value created by the investment and deployment of the monitoring agent was driven by operational efficiencies such as the reduction in the number of on-site visits and reduced travel costs as well as accelerated enrolment and database lock timelines."
For sponsors running many programmes simultaneously, the portfolio-level impact is substantial. Dr Pamela Tenaerts, CMO at Medable, said: "For a sponsor with 20 active indications, deploying a clinical monitoring agent across Phase II and III studies could generate as much as $226m in incremental portfolio eNPV. For a sponsor with 50 active indications, that figure could jump to as much as $565m."
AI adoption spreading across the drug development pipeline
AI is being adopted more widely across clinical trial workflows as sponsors see its potential for accelerating drug development. At the American Society for Clinical Oncology meeting earlier in 2026, experts noted a rise in AI-related abstracts, with the technology being used at every stage - from identifying drug targets to analysing clinical data.
Venture financing deals involving AI in drug development have grown by more than 400% between 2014 and 2024, according to GlobalData. One barrier remains: regulators are struggling to keep pace with the technology, which makes it harder for sponsors to implement AI-driven workflow improvements.
For IT and development professionals, the findings point to a concrete opportunity. The study indicates that AI monitoring agents get evaluated not as "experimental tech" but by financial metrics like ROI and eNPV - the same benchmarks that justify other enterprise software investments.
The effect on timelines is equally relevant. This 18-week acceleration is not just a medical industry trend; it reflects what AI agents can do when they take over structured, repetitive workflows: shrink cycle times and reduce costs, even in highly regulated environments.
Why this matters for IT and development professionals
Clinical trials are a highly regulated, high-cost industry - the most adversarial environment for software change you can find. The fact that AI-based monitoring agents are being deployed and showing measurable financial value there, with an 82-times ROI, signals a trend that extends far beyond pharma.
For IT and development teams in any industry, the takeaway is direct. The key to ROI is not just building an agent but embedding it into a workflow with clear cost drivers - here it was the reduction of on-site visits, travel costs, and accelerated database lock. Every tool you build should have that kind of explicit cost model attached.
If you're looking to build or deploy these kinds of workflow-focused agents, training in AI agents and automation is increasingly relevant. The clinical trial example shows that the people who win with this technology are the ones who can pin a financial number to every hour of work they automate.
Your membership also unlocks:
